US-based medical device supplier and women’s healthcare products developer MedGyn has completed the acquisition of Thomas Medical from Biomerics through one of its subsidiaries.
The financial terms of the deal were not disclosed.
Based in Indianapolis, US, Thomas Medical develops and manufactures single-use medical devices and accessories, including HS catheters and procedure trays, uterine manipulators (UMI), injectors, endometrial samplers, IUI catheters and LEEP/LLETZ electrodes.
These products are Food and Drug Administration (FDA)-cleared and CE-marked.
MedGyn CEO and chairman Lakshman Agadi said: “This acquisition underscores MedGyn’s strong commitment to both patients and healthcare professionals by continuing to provide trusted products and services in women’s healthcare.
“While we focus on domestic manufacturing, the breadth of our distribution network is global and includes over 140 countries. We look forward to providing our customers with reliable access to Thomas Medical’s high-quality portfolio of products.”
Following the acquisition, Thomas Medical will operate as an independent division of MedGyn. It will retain its brand name and continue to manufacture all products in the US without any disruption.
In a separate development, diagnostic and therapeutic medical technology company Laborie Medical Technologies (LABORIE) has signed an agreement to acquire GI Supply in partnership with growth equity company Signet Healthcare Partners.
GI Supply provides endoscopy and paracentesis products for gastroenterologists, colorectal surgeons and interventional radiologists.
GI Supply, which will continue to operate independently, will be led by its current CEO Kristi Dahlke and its existing leadership team.
LABORIE president and CEO Michael Frazzette said: “At LABORIE, we are committed to helping improve lives by enabling our clinical customers and their patients with relevant solutions for their needs. We do this organically, as well as through strategic acquisitions.
“With the acquisition of GI Supply, we immediately enhance LABORIE’s gastroenterology product offering and sales channel in the US and internationally. This is an important step in the evolution of our GI business.”